Fundraising Fox3B Future Health Fund — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)
Co-investorsCDP Venture CapitalSeroba Life SciencesV-Bio VenturesVI PartnersVertis SGRClaris Ventures+1 more
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investorsCTI Life Sciences Fund L.P.adMare BioInnovationsOmnes CapitalPanacea VentureSeventure Partners
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investorsAlbionVCBioGeneration VenturesEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.